Ardian acquired a majority stake in Sintetica from the majority shareholder Daphne and the owner family. The transaction was structured as a partnership, with the existing shareholders and management team reinvesting via a significant minority stake to maintain continuity. At the time of the deal, Sintetica was in a phase of hyper-growth (31% CAGR between 2016-2018). Ardian's investment was designed to accelerate the company's internationalization—expanding its reach beyond the 45 countries it already served—and to fuel R&D for new patented, "ready-to-use" drug delivery systems that optimize hospital efficiency and patient safety.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.